Kidney Cancer News and Research

RSS
Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Detailed analysis of epigenetics of Wilms tumor reveals similarities to stem cells

Detailed analysis of epigenetics of Wilms tumor reveals similarities to stem cells

Ablation technique as affective as conventional surgery for treating kidney cancer

Ablation technique as affective as conventional surgery for treating kidney cancer

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Sunitinib not effective in patients with papillary RCC: Researchers

Sunitinib not effective in patients with papillary RCC: Researchers

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Researchers discover key gene that promotes development of common kidney cancer

Researchers discover key gene that promotes development of common kidney cancer

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Researchers discover biological pathway signature of ccRCC

Researchers discover biological pathway signature of ccRCC

Cancer Research UK launches new cancer centre in Leeds

Cancer Research UK launches new cancer centre in Leeds

152 research and training grants awarded to researchers at 93 institutions nationwide

152 research and training grants awarded to researchers at 93 institutions nationwide

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

Total kidney removal not beneficial for elderly patients with confined kidney tumors

Total kidney removal not beneficial for elderly patients with confined kidney tumors

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.